FIbrocell Science Announces Exclusive Technology License Agreements with UCLA to Advance the Development of Personalized Cell

  FIbrocell Science Announces Exclusive Technology License Agreements with
  UCLA to Advance the Development of Personalized Cell Therapies

 Expands Company’s leading-edge technologies in fibroblasts and stem cells to
                       create autologous cell therapies

Business Wire

EXTON, Pa. -- June 17, 2014

Fibrocell Science, Inc., (NYSE MKT:FCSC), an autologous cell therapy company
primarily focused on developing first-in-class treatments for rare and serious
skin and connective tissue diseases with high unmet medical needs, announced
today that it has entered into an exclusive license agreement with The Regents
of the University of California. Under the agreement, Fibrocell acquired the
rights to commercially apply patented discoveries and technologies resulting
from the ongoing scientific collaboration between the University of California
at Los Angeles (UCLA) and Fibrocell Science.

The technologies from the UCLA collaboration and exclusive license agreements
enable Fibrocell to expand its proprietary Personalized Biologics platform
which uses human fibroblasts and stem cells from skin to create localized
therapies that are compatible with the unique biology of each patient.
Specifically, the newly licensed patents and technologies relate to two
advancements in the therapeutic application of cell therapies:

  *Methods for use of autologous fibroblasts for developing personalized
    biologics with bone morphogenetic protein 2 (BMP-2) for bone repair,
    opening the potential for optimal therapeutic effect of BMP-2 at the site
    of disease in surgical procedures involving bone repair;
  *Methods for producing highly stable, commercially viable induced
    pluripotent stem cells (iPSCs) from adult skin cells, opening the
    potential to expand the usage of iPSCs in autologous cell therapies.

“The technologies from these licenses further strengthen Fibrocell’s rich
development platform,” said David Pernock, chairman and chief executive
officer of Fibrocell. “These potentially transformational technologies offer
partnering opportunities for Fibrocell.”

The license agreements build upon an existing research collaboration between
Fibrocell and UCLA that has already yielded discoveries and technologies
related to stem cells and regenerative cells in human skin. Such research is
led by James A. Byrne, Ph.D., an Assistant Professor in UCLA’s Department of
Molecular and Medical Pharmacology at the Eli and Edythe Broad Center of
Regenerative Medicine and Stem Cell Research.

About Fibrocell Science, Inc.

Fibrocell Science, Inc. (NYSE MKT:FCSC) is an autologous cell therapy company
primarily focused on developing first-in-class treatments for rare and serious
skin and connective tissue diseases with high unmet medical needs. Based on
its proprietary autologous fibroblast technology, Fibrocell is pursuing
breakthrough medical applications of azficel-T for restrictive burn scarring
and vocal cord scarring. The company’s collaboration with Intrexon Corporation
(NYSE:XON), a leader in synthetic biology, includes using genetically-modified
fibroblasts for treating rare and serious skin and connective tissue diseases
for which there are no currently approved products. For additional
information, visit www.fibrocellscience.com.

About UCLA

UCLAis California’s largest university, with an enrollment of more than
40,000 undergraduate and graduate students. The UCLA College of Letters and
Science and the university’s 11 professional schools feature renowned faculty
and offer 337 degree programs and majors. UCLA is a national and international
leader in the breadth and quality of its academic, research, health care,
cultural, continuing education and athletic programs. Seven alumni and six
faculty have been awarded the Nobel Prize.

Forward-Looking Statements

This press release contains, and our officers and representatives may from
time to time make, statements that are “forward-looking statements” within the
meaning of the safe harbor provisions of the U.S. Private Securities
Litigation Reform Act of 1995. Examples of forward-looking statements include,
among others, statements we make regarding (i) our ability to develop
breakthrough therapies for the treatment of skin and connective tissues
diseases and (ii) our ability to successfully leverage our relationship with
UCLA to expand our proprietary Personalized Biologics platform. These
forward-looking statements rely on a number of assumptions concerning future
events and are subject to a number of risks, uncertainties, and other factors,
many of which are outside of Fibrocell Science’s control. Important factors
that could cause our actual results and financial condition to differ
materially from those indicated in the forward-looking statements include,
among others, the following: (i) uncertainties relating to the initiation and
completion of clinical trials; (ii) whether clinical trial results will
validate and support the safety and efficacy of azficel-T; and (iii) our
ability to establish additional strategic partnerships, as well as those set
forth under the caption “Item 1A. Risk Factors” in Fibrocell Science’s most
recent Form 10-K filing, as updated in “Item 1A. Risk Factors” in Fibrocell
Science’s most recent Form 10-Q filing. Any forward-looking statement made by
us in this press release is based only on information currently available to
us and speaks only as of the date on which it is made. In addition, Fibrocell
Science operates in a highly competitive and rapidly changing environment, and
new risks may arise. Accordingly, you should not place any reliance on
forward-looking statements as a prediction of actual results. Fibrocell
Science disclaims any intention to, and undertakes no obligation to, update or
revise any forward-looking statement. You are also urged to carefully review
and consider the various disclosures in Fibrocell Science’s most recent annual
report on Form 10-K, our most recent Form 10-Q as well as other public filings
with the SEC since the filing of Fibrocell Science’s most recent annual
report.

Contact:

Corporate:
Fibrocell Science, Inc.
Gregory Weaver, +1-484-713-6000
Senior Vice President and Chief Financial Officer
gweaver@fibrocellscience.com
or
Investor Relations:
S.A. Noonan Communications, LLC
Susan Noonan, 212-966-3650
susan@sanoonan.com
 
Press spacebar to pause and continue. Press esc to stop.